Bicara Therapeutics Inc. (BCAX) Financial Statements

79 Followers

Bicara Therapeutics Inc. Financial Overview

Bicara Therapeutics Inc.'s market cap is currently $1.42B. The company's EPS TTM is $-2.53; its P/E ratio is -6.67; Bicara Therapeutics Inc. is scheduled to report earnings on March 30, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Income	$ -155.60M	$ -82.39M	$ -39.89M	$ -37.66M
EBITDA	$ -155.60M	$ -82.33M	$ -39.87M	$ -37.72M
Net Income	$ -137.95M	$ -68.00M	$ -51.98M	$ -37.84M
Balance Sheet
Cash & Short-Term Investments	$ 414.80M	$ 489.71M	$ 230.44M	$ 4.16M
Total Assets	$ 430.99M	$ 569.20M	$ 233.98M	$ 6.70M
Total Debt	$ 1.71M	$ 738.00K	$ 657.00K	$ 0.00
Net Debt	$ -94.97M	$ -488.97M	$ -229.78M	$ -4.16M
Total Liabilities	$ 29.54M	$ 77.32M	$ 15.47M	$ 23.98M
Stockholders' Equity	$ 401.45M	$ 491.88M	$ 218.51M	$ -17.28M
Cash Flow
Free Cash Flow	$ -107.11M	$ -74.82M	$ -46.21M	$ -32.27M
Operating Cash Flow	$ -106.83M	$ -74.75M	$ -45.63M	$ -32.08M
Investing Cash Flow	$ -318.45M	$ -9.00K	$ -586.00K	$ -192.00K
Financing Cash Flow	$ 32.26M	$ 334.03M	$ 272.50M	$ 31.70M

Currency in USD

Bicara Therapeutics Inc. Earnings and Revenue History

Income Statement >

Bicara Therapeutics Inc. Debt to Assets

Balance Sheet >

Bicara Therapeutics Inc. Cash Flow

Cash Flow >

Bicara Therapeutics Inc. Forecast EPS vs Actual EPS

Earnings >